Over the past five years, biotech investment has experienced the fastest development in China. Pharmaceutical companies have become a rising force that has attracted increasing amount of capital.
Transcenta is a biotech company that is riding this momentum.
In an interview with Transcenta’s chief executive Xueming Qian and chairman Jonathan Zhao, the two founders share their vision and future plans for the young company. Transcenta was founded in January this year when HJB and MabSpace came together. HJB was focused on bioprocessing technology that accelerates manufacturing, while MabSpace provides discovery, clinical stage research for biologic medicines.